Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 8/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.37 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | GRK6 | P43250 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10173105 | 0.85 | HTR1A (0.41) | F10TNIKBRD9CCNCCDK8 | |
| SCHEMBL10140917 | 0.84 | F10 (0.41) | F10TNIKPRSS1 | |
| SCHEMBL10140047 | 0.83 | F10 (0.40) | F10TNIKBRD9GALR3LMNA | |
| SCHEMBL7966289 | 0.82 | F10 (0.39) | F10TNIKBRD9GALR3LMNA | |
| SCHEMBL10140048 | 0.80 | F10 (0.38) | F10TNIKGALR3LMNATSHR | |
| SCHEMBL10140720 | 0.80 | PDPK1 (0.39) | HTTCDK2 | |
| SCHEMBL10140703 | 0.80 | CA12 (0.39) | CDK2 | |
| SCHEMBL10140058 | 0.79 | F10 (0.49) | F10PRSS1 | |
| SCHEMBL10140741 | 0.76 | KDM4E (0.42) | HTT | |
| SCHEMBL10140767 | 0.75 | NPC1 (0.43) | CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | F9, F12, F8 | F10 11/4885TNIK 2238/4885BRD9 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.